Screening of tumor necrosis factor receptor-associated factor 6 as a candidate gene for inflammatory bowel disease

Scandinavian Journal of Gastroenterology

Volumn 41, Issue 4, 2006, Pages 424-429

  Lappalainen, Maarit ^a,b   Paavola Sakki, Paulina ^b   Halme, Leena ^c   Turunen, Ulla ^c   Heliö, Tiina ^c   Färkkilä, Martti ^c   Kontula, Kimmo ^a,b  

^a BIOMEDICUM HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Inflammatory bowel disease; NF B; Screening; TRAF6; Variation

Indexed keywords

ACETYLSALICYLIC ACID; IMMUNOSUPPRESSIVE AGENT; METRONIDAZOLE; STEROID; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6;

ADAPTIVE IMMUNITY; ADULT; ARTICLE; CHROMOSOME 11P; CONTROLLED STUDY; CROHN DISEASE; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA SEQUENCE; ENTERITIS; EXON; FEMALE; GENE MAPPING; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC SCREENING; HUMAN; IMMUNITY; INNATE IMMUNITY; INTRON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMOSOMES, HUMAN, PAIR 11; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; HUMANS; LINKAGE (GENETICS); MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; TNF RECEPTOR-ASSOCIATED FACTOR 6;

EID: 33646429208     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520500265166     Document Type: Article

References (33)

1. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003;124:521-36.
2. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-33.
3. Duerr RH. Update on the genetics of inflammatory bowel disease. J Clin Gastroenterol 2003;37:358-67.
4. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
5. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et alBonen DK, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
6. van Heel DA, Fisher SA, Kirby A, Daly MJ, Rioux JD, Lewis CM. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004;13:763-70.
7. Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am J Gastroenterol 2004;99:2393-404.
8. Heliö T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003;52:558-62.
9. Philpott DJ, Girardin SE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol Immunol 2004;41:1099-108.
10. Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 2000;254:14-24.
11. Bradley JR, Pober JS. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 2001;20:6482-91.
12. Chung JY, Park YC, Ye H, Wu H. All TRAFs are not created equal: common and distinct molecular mechanisms of TRAF-mediated signal transduction. J Cell Sci 2002;115:679-88.
13. Ishida T, Mizushima S, Azuma S, Kobayashi N, Tojo T, Suzuki K, et al. Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 1996;271:28745-8.
14. Ye H, Arron JR, Lamothe B, Cirilli M, Kobayashi T, Shevde NK, et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002;418:443-7.
15. Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol 2004;38:218-24.
16. Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-24.
17. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999;4:353-62.
18. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475-80.
19. Halme L, Turunen U, Helio T, Paavola P, Walle T, Miettinen A, et al. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand J Gastroenterol 2002;37:692-8.
20. Helio T, Halme L, Lappalainen M, Fodstad H, Paavola-Sakki P, Turunen U, et al. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003;52:558-62.
21. Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel DV. TRAF6 is a signal transducer for interleukin-1. Nature 1996;383:443-6.
22. Grech A, Quinn R, Srinivasan D, Badoux X, Brink R. Complete structural characterisation of the mammalian and Drosophila TRAF genes: implications for TRAF evolution and the role of RING finger splice variants. Mol Immunol 2000;37:721-34.
23. Mukundan L, Bishop GA, Head KZ, Zhang L, Wahl LM, Suttles J. TNF receptor-associated factor 6 is an essential mediator of CD40-activated proinflammatory pathways in monocytes and macrophages. J Immunol 2005;174:1081-90.
24. Lomaga MA, Henderson JT, Elia AJ, Robertson J, Noyce RS, Yeh WC, et al. Tumor necrosis factor receptor-associated factor 6 (TRAF6) deficiency results in exencephaly and is required for apoptosis within the developing CNS. J Neurosci 2000;20:7384-93.
25. Bernstein CN, Leslie WD. Review article: osteoporosis and inflammatory bowel disease. Aliment Pharmacol Ther 2004;19:941-52.
26. Ghosh S, Cowen S, Hannan WJ, Ferguson A. Low bone mineral density in Crohn's disease, but not in ulcerative colitis, at diagnosis. Gastroenterology 1994;107:1031-9.
27. Lin CL, Moniz C, Chambers TJ, Chow JW. Colitis causes bone loss in rats through suppression of bone formation. Gastroenterology 1996;111:1263-71.
28. Qasim A, Seery J, Morain CA. Osteoporosis in newly diagnosed inflammatory bowel disease. Gastroenterology 2001;121:504-6.
29. Chu CS, Trapnell BC, Murtagh JJ, Jr, Moss J, Dalemans W, Jallat S, et al. Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. EMBO J 1991;10:1355-63.
30. Chu CS, Trapnell BC, Curristin S, Cutting GR, Crystal RG. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat Genet 1993;3:151-6.
31. Chillon M, Casals T, Mercier B, Bassas L, Lissens W, Silber S, et al. Mutations in the cystic fibrosis gene in patients with congenital absence of the vas deferens. N Engl J Med 1995;332:1475-80.
32. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al. Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 2002;3:248-54.
33. Bream JH, Carrington M, O'Toole S, Dean M, Gerrard B, Shin HD, et al. Polymorphisms of the human IFNG gene noncoding regions. Immunogenetics 2000;51:50-8.